Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2007
Business Overview: Alnylam is a biopharmaceutical company developing therapeutics based on RNA interference (RNAi). The company has no approved products and generates revenue primarily through strategic alliances, government contracts, and licensing fees. As of September 30, 2007, the company had an accumulated deficit of $227.7 million.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2007 |
Nine Months Ended Sep 30, 2007 |
Nine Months Ended Sep 30, 2006 |
|---|---|---|---|
| Net Revenues | $16,315 | $32,665 | $19,949 |
| Operating Expenses | $67,653 | $122,950 | $49,459 |
| Loss from Operations | $(51,338) | $(90,285) | $(29,510) |
| Net Loss | $(52,792) | $(87,128) | $(26,170) |
| Net Loss Per Share (Basic/Diluted) | $(1.35) | $(2.29) | $(0.83) |
| Cash and Cash Equivalents | $200,547 | $200,547 | $35,516 |
| Marketable Securities | $267,831 | $267,831 | $89,305 |
| Total Assets | $505,091 | $505,091 | $240,006 |
| Total Liabilities | $312,156 | $312,156 | $38,832 |
| Deferred Revenue (Current + Long-term) | $278,703 | $278,703 | $17,930 |
Liquidity: Cash, cash equivalents, and marketable securities totaled $468.4 million as of September 30, 2007, a significant increase from $217.3 million at year-end 2006. The company has equipment lines of credit with Oxford Finance and Lighthouse Capital Partners, with an aggregate outstanding balance of $7.7 million.
Material Changes vs. Prior Period
- Revenue Surge: Net revenues increased 99% for the three months and 64% for the nine months ended September 30, 2007, compared to the prior year periods. This was driven primarily by the August 2007 alliance with Roche and the termination of the Merck collaboration.
- Roche Alliance: In July/August 2007, Alnylam entered a major agreement with Roche, receiving $331.0 million in upfront payments ($273.5 million license fee, $42.5 million stock purchase, $15.0 million asset sale). $278.5 million was recorded as deferred revenue to be recognized over five years.
- Expense Increases: Operating expenses rose 302% for the quarter and 149% for the nine months. Research and Development (R&D) expenses increased 370% (quarterly) and 184% (nine-month) due to $27.5 million in license fees payable to third parties (primarily Isis) triggered by the Roche deal, plus increased clinical trial costs for the RSV program.
- Merck Termination: The collaboration with Merck was terminated in September 2007. Alnylam recognized $3.5 million of remaining deferred revenue from this agreement in Q3 2007.
- Joint Venture: In September 2007, Alnylam formed Regulus Therapeutics LLC with Isis Pharmaceuticals to develop microRNA (miRNA) therapeutics. Alnylam contributed $10.0 million cash for a 49% interest.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur additional losses over the next several years. Revenues are expected to continue deriving primarily from strategic alliances and government contracts. The company believes current resources, including the Roche alliance proceeds, are sufficient to fund operations for at least the next several years.
- Revenue Recognition: The $278.5 million deferred from the Roche deal is being recognized on a straight-line basis over five years because the company cannot currently estimate the total level of effort required for the collaboration services.
- Key Risks:
- Technology Risk: RNAi is an unproven technology; no siRNA-based drugs have received regulatory approval. Challenges include delivery mechanisms and off-target effects.
- Development Risk: High failure rate in clinical trials. The lead program (ALN-RSV01) is in Phase II experimental infection trials.
- Collaboration Dependence: Significant reliance on partners (Roche, Novartis, Medtronic) for funding and commercialization. Termination of these agreements would materially harm the business.
- Intellectual Property: Risks related to patent litigation and the validity of core RNAi patents (e.g., Kreutzer-Limmer patents facing opposition).
Investor Verification Checklist
- Roche Revenue Recognition: Verify the five-year straight-line amortization schedule for the $278.5 million deferred revenue and the conditions under which the company might switch to a proportional performance method.
- License Fee Obligations: Confirm the $27.5 million in license fees paid to Isis and other licensors triggered by the Roche deal and any future contingent payments.
- Cash Burn Rate: Assess the sustainability of the $468.4 million cash position against the projected R&D spend, noting the significant increase in operating expenses.
- Regulus Therapeutics: Review the terms of the joint venture with Isis, specifically the 49% ownership stake and the $10 million initial funding obligation.
- Patent Status: Monitor the status of opposition proceedings against the Kreutzer-Limmer patents at the European Patent Office, which are critical to the company's IP portfolio.